ISO 10993 Cytotoxicity Testing: A Complete Technical Guide to In Vitro Biocompatibility Evaluation

ISO 10993 cytotoxicity testing is the foundational in vitro biocompatibility test required for medical devices seeking regulatory approval in major global markets. Performed in accordance with ISO 10993-5, this test evaluates whether a device or material releases substances that can damage living cells, providing a rapid and sensitive first screen for biological safety. This article explains the technical principles, sample requirements, test methods, acceptance criteria, and regulatory applications of ISO 10993 cytotoxicity testing.

Technical Overview

ISO 10993 cytotoxicity testing refers to the in vitro evaluation of cell toxicity caused by medical devices, biomaterials, or their extracts, as specified in ISO 10993-5 (Tests for in vitro cytotoxicity), which is part of the ISO 10993 series (Biological evaluation of medical devices). Because cytotoxicity testing is fast, sensitive, and cost-effective, it is universally recognized by regulators such as the US FDA, EU notified bodies under the EU MDR, China NMPA, and Japan PMDA as the first biocompatibility test that should be performed on any new medical device or material.

The test is supported by two companion standards: ISO 10993-1, which defines the biological evaluation framework within a risk management process, and ISO 10993-12, which governs sample preparation and reference materials. The core principle is straightforward: cultured mammalian cells are exposed to a test sample either directly or indirectly, or to an extract prepared from the sample, and the resulting cellular injury is assessed by microscopic morphology, cell viability measurement, or cell proliferation analysis.

A finding of cytotoxicity does not automatically mean the device is unsafe, but it signals the presence of potentially harmful leachable substances—such as residual monomers, catalysts, plasticizers, sterilant residues, or processing contaminants—that must be investigated through risk assessment before the product can be cleared for clinical use.

Testing Samples

Finished Medical Devices

The preferred test sample is the finished device in its final form, final manufacturing condition, and final sterilization state. Testing the actual commercial product ensures that all materials, surface treatments, coatings, adhesives, printing inks, and sterilization effects are captured in the evaluation.

Materials and Components

During early-stage development, raw materials, polymer resins, elastomers, coatings, adhesives, colorants, and packaging components can be screened individually. This material-level screening helps identify the source of toxicity when a finished device fails, and supports supplier qualification and material substitution decisions.

Test Extracts

For most devices, testing is performed on extracts rather than the solid sample itself. In accordance with ISO 10993-12, extracts are typically prepared under the following conditions:

• Extraction media: a polar medium (e.g., serum-free MEM or saline) and, when justified, a non-polar medium (e.g., sesame oil or cottonseed oil) to cover both hydrophilic and hydrophobic leachables.
• Extraction conditions: 37 ± 1 °C for 24 ± 2 hours is the standard condition; accelerated or exaggerated conditions may be used when clinically justified.
• Extraction ratios: for regular-shaped devices, 6 cm² per mL (surface area) for samples 0.5–1 mm thick, 3 cm² per mL for samples thicker than 1 mm, 0.1–0.2 g per mL by mass for irregular or absorbent materials.

Special Sample Situations

Composite devices, combination products, degradation-based materials, and devices with dynamic or blood-contacting functions may require modified extraction schemes, additional extraction media, or protocol justifications documented in the test plan.

Testing Items

ISO 10993-5 defines three categories of cytotoxicity test items, and laboratories typically select one or a combination based on the nature, shape, and intended use of the device:

• Extract test (elution method): cells are exposed to the test extract; suitable for almost all device types and the most widely used approach.
• Direct contact test: the sample is placed directly on the cell monolayer; suitable for evaluating surface effects of low-density, non-toxic solid materials.
• Indirect contact tests: includes the agar diffusion (agar overlay) test for solid samples and the filter diffusion test for screening diffusible toxic components.

Depending on the endpoint, the evaluation can be qualitative (microscopic assessment of cell morphology, malformation, detachment, and lysis, graded 0–4 for reactivity) or quantitative (measurement of cell viability or proliferation using colorimetric or fluorometric bioassays).

Testing Methods

Cell System Selection

The mouse fibroblast cell line L929 is the reference cell line recommended by ISO 10993-5 and is used in the majority of accredited cytotoxicity assays. Alternative systems such as BALB/c 3T3 cells, primary cells, or organ-specific cells may be used when scientifically justified.

Quantitative Extract Test (MTT Method)

The MTT colorimetric assay is the most common quantitative method. The standard workflow is as follows:

• Seed L929 cells into 96-well culture plates and incubate until a uniform monolayer forms (approximately 24 hours).
• Replace the culture medium with the test extract, and incubate for 24 ± 2 hours (48-hour or 72-hour exposure may be specified in the protocol).
• Add MTT reagent; viable cells with active mitochondrial dehydrogenases convert the yellow tetrazolium salt into purple formazan crystals.
• Dissolve the formazan and measure absorbance at approximately 570 nm using a microplate reader.
• Calculate cell viability as a percentage of the untreated blank control.

Alternative quantitative readouts include XTT, WST-8 (CCK-8), neutral red uptake, total protein staining, and clonogenic assays, which are selected based on sample characteristics and potential assay interference.

Controls and Acceptance Criteria

Each test must include a negative control (typically high-density polyethylene, HDPE) and a positive control (such as latex, 0.1% sodium dodecyl sulfate, or dilute organotin-containing PVC), along with a blank control. The controls validate the sensitivity of the cell system and the test conditions.

For quantitative assays, ISO 10993-5 specifies that a test sample is considered cytotoxic if cell viability is reduced to below 70% of the blank control. For qualitative assays, a reactivity grade of 2 or higher (on the 0–4 scale) generally indicates a cytotoxic response requiring further investigation.

Test Report

A compliant report includes complete sample and extraction information, cell line details, test method description, control results, individual and mean viability values, reactivity grading, photographic documentation of morphology where applicable, and a clear pass/fail conclusion against the acceptance criteria.

Applications

ISO 10993 cytotoxicity testing is applied across the entire product lifecycle of medical devices:

• Regulatory submissions: required for China NMPA Class II and Class III device registration, US FDA 510(k) and PMA submissions, EU MDR CE technical documentation, and registrations in Japan, Korea, Canada, and Brazil.
• Research and development: rapid screening of candidate materials, coatings, adhesives, and surface treatments before committing to expensive animal studies.
• Change control: re-evaluation after material supplier changes, formulation modifications, process changes, or changes in sterilization method.
• Failure investigation: isolating the toxic component when unexpected biological responses occur.
• Product categories: catheters and infusion sets, implants and orthopedic devices, wound dressings, dental materials, syringes and needles, surgical instruments, gloves, condoms, contact and intraocular lenses, in vitro diagnostic consumables, and medical packaging.

Because the test is conducted on mammalian cell cultures, it reduces animal use in alignment with the 3Rs principle (replacement, reduction, refinement) and delivers results within weeks rather than months, making it an efficient gateway test within the overall ISO 10993 biocompatibility battery, which may also include sensitization, irritation, systemic toxicity, genotoxicity, and hemocompatibility testing depending on device contact category and duration.

FAQ

Which part of ISO 10993 covers cytotoxicity testing?

Cytotoxicity testing is covered by ISO 10993-5 (Tests for in vitro cytotoxicity), with sample preparation governed by ISO 10993-12 and the overall evaluation strategy defined by ISO 10993-1. Laboratories typically cite all three standards in the test report.

How long does the test take?

A standard quantitative extract test (MTT method) typically requires approximately 3 to 4 weeks from sample receipt to final report, including extraction, cell culture, exposure, and reporting. Additional time may be needed for complex samples requiring multiple extraction media or justification studies.

How much sample is required?

The required quantity depends on the extraction ratio and the number of media used. As a practical guideline, laboratories often request 4 g or 100–150 cm² of material, or a representative number of finished devices, to cover duplicate testing with both polar and non-polar extraction where applicable.

What does a result below 70% viability mean?

A viability below 70% of the blank control indicates the sample has cytotoxic potential under the test conditions. This triggers follow-up investigation, such as identifying leachable substances through extractables and leachables studies, reviewing residuals from manufacturing or sterilization, adjusting post-curing or cleaning processes, or substituting materials.

Should I choose the extract test or the direct contact test?

The extract (elution) test is the default choice for most devices because it evaluates all leachable substances and applies to virtually any sample geometry. Direct contact and indirect contact methods are useful for solid materials where surface effects or limited diffusion are of specific concern, and can be run in parallel with the extract test.

Does passing the cytotoxicity test mean the device is biocompatible?

No. Cytotoxicity is only one endpoint within the ISO 10993-1 evaluation plan. Depending on the nature of body contact (surface, external communicating, or implant) and contact duration (limited, prolonged, or long-term), additional tests such as sensitization, intracutaneous irritation, systemic toxicity, genotoxicity, implantation, or hemocompatibility may also be required to conclude the biological safety evaluation.

Which accreditation should the testing laboratory hold?

For regulatory submissions, testing should be performed by a laboratory with ISO/IEC 17025 accreditation covering the relevant ISO 10993-5 methods, and ideally with GLP compliance or a proven track record of reports accepted by the target regulatory authorities such as NMPA, FDA, and EU notified bodies.